The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users

Harm Reduction Journal

Volumn 5, Issue , 2008, Pages

  Norman, Josephine ^a   Walsh, Nick M ^a,e   Mugavin, Janette ^a   Stoové, Mark A ^a,b   Kelsall, Jenny ^a,c   Austin, Kirk ^a   Lintzeris, Nick ^a,d  

^a TURNING POINT ALCOHOL AND DRUG CENTRE   (Australia)

^b MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^c Victorian Drug Users Group (VIVAIDS)   (Australia)

^d Drug Health Services   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; AUSTRALIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMMUNITY CARE; COMORBIDITY; DATA ANALYSIS; DRUG ABUSE; FEMALE; HEPATITIS C VIRUS; HUMAN; INTERVIEW; MALE; PATIENT ATTITUDE; PEER COUNSELING; PEER GROUP; PSYCHOLOGICAL WELL BEING; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; SUBSTANCE ABUSE; VIRUS HEPATITIS;

EID: 42049087886     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/1477-7517-5-8     Document Type: Article

References (31)

1. NCHECR HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report. National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Sydney, NSW; Australian Institute of Health and Welfare, Canberra, ACT. 2005
2. Law MG Dore GJ Bath N Thompson S Crofts N Dolan K Giles W Gow P Kaldor J Loveday S Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001 International Journal of Epidemiology 2003, 32:717-724 10.1093/ije/dyg101 14559738
3. Robotin MC Copland J Tallis G Coleman D Giele C Carter L Spencer J Kaldor JM Dore GJ Surveillance for newly acquired hepatitis C in Australia Journal of Gastroenterology and Hepatology Blackwell Publishing Asia Carlton South, Australia 2004, 19(3):283-288 10.1111/ j.1440-1746.2003.03270.x 14748875
4. Crofts N Hopper JL Bowden DS Breschkin AM Milner R Locarnini SA Hepatitis C virus infection among a cohort of Victorian injecting drug users. Med J Aust 1993, 159(4):237-241 7692222
5. Crofts N Jolley D Kaldor J van Beek I Wodak A Epidemiology of hepatitis C virus infection among injecting drug users in Australia J Epidemiol Community Health 1997, 51(6):692-697 9519134
6. MacDonald MA Wodak AD Dolan KA van Beek I Cunningham PH Kaldor JM Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995-1997 Medical Journal of Australia 2000, 172(2):57-61 10738473
7. van Beek I Buckley R Stewart M MacDonald M Kaldor J Risk factors for hepatitis C virus infection among injecting drug users in Sydney Genitourin Med 1994, 70(5):321-324 8001943
8. van Beek I Dwyer R Dore GJ Luo K Kaldor JM Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study British Medical Journal Br Med Assoc 1998, 317(7156):433-437 28635 9703523
9. Strader DB Wright T Thomas DL Seeff LB Diagnosis, management, and treatment of hepatitis C Hepatology 2004, 39(4):1147-1171 10.1002/ hep.20119 15057920
10. Edlin BR Hepatitis C prevention and treatment for substance users in the United States: Acknowledging the elephant in the living room The International journal on drug policy 2004, 15(2):81-91 1770941 17225853 10.1016/j.drugpo.2003.10.007
11. Backmund M Meyer K Von Zielonka M Eichenlaub D Treatment of hepatitis C infection in injection drug users Hepatology 2001, 34(1):188-193 10.1053/ jhep.2001.25882 11431750
12. Sylvestre DL Loftis JM Hauser P Genser S Cesari H Borek N Kresina TF Seeff L Francis H Co-occurring hepatitis C, substance use, and psychiatric illness: Treatment issues and developing integrated models of care Journal of Urban Health Springer 2004, 81(4):719-734 15466851
13. Sylvestre DL Treating hepatitis C in methadone maintenance patients: An interim analysis. Drug Alcohol Depend 2002, 67(2):117-123 10.1016/ S0376-8716(02)00010-8 12095661
14. Wong J Sylvestre D Siebert U Cost-effectiveness of treatment of HCV in injecting drug users Hepatitis C and injecting drug use: Impact, costs and policy options Lisbon, European Monitoring Centre for Drugs and Drug Addiction Jager J, Limburg W, Kretzschmar M, Postma M, Wiessing L 2004:219-2244
15. Sylvestre DL Treating hepatitis C virus infection in active substance users. Clinical Infectious Diseases University of Chicago Press Chicago, USA 2005, 40(Suppl 5):S321-S324 10.1086/427447 15768341
16. Stoove MA Gifford SM Dore GJ The impact of injecting drug use status on hepatitis C-related referral and treatment Drug Alcohol Depend 2005, 77(1):81-86 10.1016/j.drugalcdep.2004.07.002 15607844
17. Doab A Treloar C Dore GJ Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia. Clinical Infectious Diseases University of Chicago Press Chicago, USA 2005, 40(Suppl 5):S313-S320 10.1086/427446 15768340
18. Neri S Bruno CM Abate G Ierna D Mauceri B Cilio D Bordonaro F Pulvirenti D Italiano C Caruso L Controlled clinical trial to assess the response of recent heroin abusers with chronic hepatitis C virus infection to treatment with interferon alpha-n2b. Clin Ther 2002, 24(10):1627-1635 10.1016/S0149-2918(02)80065-0 12462291
19. Soriano V Garcia-Samaniego J Bravo R Gonzalez J Castro A Castilla J Martinez-Odriozola P Colmenero M Carballo E Suarez D Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996, 23(3):585-591 8879784
20. Van Thiel D Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse The American Journal of Gastroenterology Blackwell Synergy 2003, 98(10):2281-2288 14572580
21. Jowett SL Agarwal K Smith BC Craig W Hewett M Bassendine DR Gilvarry E Burt AD Bassendine MF Managing chronic hepatitis C acquired through intravenous drug use QJM 2001, 94:153-158 10.1093/qjmed/94.3.153 11259690
22. Cournot M Glibert A Castel F Druart F Imani K Lauwers-Cances V Morin T Management of hepatitis C in active drugs users: Experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004, 28(7 Pt 1):533-539 15243385
23. Farley J Vasdev S Fischer B Rehm J Haydon E Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes International Journal of Prisoner Health Taylor & Francis 2005, 1(1):13-18 10.1080/17449200500157044
24. Farley JD Wong VK Chung HV Lim E Walters G Farley TA Yoshida EM Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol 2005, 19(3):153-156 15776135
25. Dalgard O Bjoro K Hellum K Myrvang B Skaug K Gutigard B Bell H Treatment of Chronic Hepatitis C in Injecting Drug Users: 5 Years' Follow-Up European Addiction Research 2002, 8(1):45-49 10.1159/000049487 11818693
26. Schaefer M Heinz A Backmund M Treatment of chronic hepatitis C in patients with drug dependence: Time to change the rules? Addiction Blackwell Publishing Oxford, UK 2004, 99(9):1167-1175 10.1111/ j.1360-0443.2004.00821.x 15317637
27. Mauss S Berger F Goelz J Jacob B Schmutz G A prospective controlled study of interferon-based therapy of chronic hepatitis C in patients on methadone maintenance Hepatology 2004, 40(1):120-124 10.1002/hep.20279 15239094
28. Sylvestre DL Zweben JE Integrating HCV services for drug users: A model to improve engagement and outcomes The International journal on drug policy 2007, 18(5):406-410 10.1016/j.drugpo.2007.01.010 17854729
29. Madden A Cavalieri W Hepatitis C prevention and true harm reduction The International journal on drug policy 2007, 18(5):335-337 10.1016/ j.drugpo.2007.06.007 17854719
30. Marlatt GA Harm Reduction: Pragmatic Strategies for Managing High-Risk Behaviors Guilford Pubn 1998
31. Salomon JA Weinstein MC Hammitt JK Goldie SJ Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population JAMA 2003, 290:228-237 10.1001/jama.290.2.228 12851278